甲磺酸奥希替尼联合含铂双药化疗对EGFR突变晚期非小细胞肺癌患者EGF及IGF相关指标的影响

Effect of Osimertinib Mesylate Combined with Platinum Containing Dual Drug Chemotherapy in Patients with EGFR Mutated Advanced Non-small Cell Lung Cancer on Related Indexes of EGF and IGF

目的:探究甲磺酸奥希替尼在晚期非小细胞肺癌患者中的疗效及对表皮生长因子(EGF)、胰岛素样生长因子(IGF)相关指标的影响。方法:将2021年1月—2022年11月厦门大学附属第一医院收治的表皮生长因子受体(EGFR)突变晚期非小细胞肺癌患者100例,根据随机数字表法分为对照组(n=50)和观察组(n=50)。对照组进行常规含铂双药化疗,观察组则在对照组化疗的基础上加用甲磺酸奥希替尼。比较两组的非小细胞肺癌治疗效果、不良反应发生情况、EGF及EGFR及IGF相关指标[胰岛素样生长因子-Ⅰ(IGF-Ⅰ)、胰岛素样生长因子-Ⅱ(IGF-Ⅱ)、胰岛素样生长因子Ⅰ受体(IGF-ⅠR)及胰岛素样生长因子结合蛋白3(IGFBP-3)]。结果:观察组的非小细胞肺癌治疗总有效率显著高于对照组,差异有统计学意义(P<0.05)。两组的不良反应发生率比较,差异均无统计学意义(P>0.05)。治疗前,两组的EGF及EGFR、IGF相关指标比较,差异均无统计学意义(P>0.05);治疗2、4个周期后,观察组的EGF及EGFR、IGF-Ⅰ、IGF-Ⅱ及IGF-ⅠR均显著低于对照组,IGFBP-3均显著高于对照组,差异均有统计学意义(P<0.05)。结论:甲磺酸奥希替尼联合治疗在EGFR突变晚期非小细胞肺癌患者中的临床效果较好,且可显著改善患者的EGF及IGF相关指标的表达,具有较高的应用价值。

Objective:To investigate the effect of Osimertinib Mesylate in patients with advanced nonsmall cell lung cancer and influence on related indexes of epidermal growth factor(EGF)and insulin like growth factor(IGF).Method:A total of 100 patients with epidermal growth factor receptor(EGFR)mutated advanced nonsmall cell lung cancer in the First Affiliated Hospital of Xiamen University from January 2021 to November 2022 were divided into control group(n=50)and observation group(n=50)by the random number table method.The control group was treated with platinum containing dual drug chemotherapy,the observation group was treated with Osimertinib Mesylate on the treatment of control group.Then the treatment effect of non-small cell lung cancer,incidence of adverse reaction,EGF and EGFR,IGF related indexes[insulin like growth factorⅠ(IGF-Ⅰ),insulin like growth factorⅡ(IGF-Ⅱ),insulin like growth factorⅠreceptor(IGF-ⅠR)and insulin like growth factor binding protein-3(IGFBP-3)]of two groups were compared.Result:The total effective rate of non-small cell lung cancer treatment of observation group was significantly higher than that of control group,the difference was statistically significant(P<0.05).There were no statistically significant differences in the incidences of adverse reactions between the two groups(P>0.05).Before the treatment,the EGF and EGFR,IGF related indexes of two groups were compared,the differences were not statistically significant(P>0.05);after 2 and 4 cycles of treatment,the levels of EGF and EGFR,IGF-Ⅰ,IGF-Ⅱand IGF-ⅠR of observation group were significantly lower than those of control group,the levels of IGFBP-3 were significantly higher than those of control group,the differences were statistically significant(P<0.05).Conclusion:The effect of Osimertinib Mesylate in patients with EGFR mutated advanced nonsmall cell lung cancer is better,and it can significantly improve the expression of related indexes of EGF and IGF,so its application value in the patients with advanced non-small cell lung cancer is higher.